Beijing Gene Key Life Technology Co., Ltd
Clinical trials sponsored by Beijing Gene Key Life Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune cell therapy takes on untreatable liver cancer Results expected Nov 2026 (estimated)
- Can a new injection boost chemotherapy against pancreatic cancer? Results expected Mar 2027 (estimated)
- Immune cell infusion aims to free ARDS patients from ventilators Results expected Jul 2027 (estimated)
-
Can a new injection boost chemotherapy against pancreatic cancer?
Disease control OngoingThis early-stage trial is testing an investigational drug called GKL-006, given alongside standard chemotherapy, in people with advanced pancreatic cancer that cannot be removed by surgery. The study aims to see if the combination is safe and tolerable, and whether it shows any p…
Phase 1/2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Immune cell therapy takes on untreatable liver cancer
Disease control OngoingThis study tests an experimental treatment called GKL-006, made from a person's own immune cells (iNKT cells), for liver cancer that cannot be surgically removed. Participants receive GKL-006 injections along with a standard procedure that blocks the tumor's blood supply (TACE). …
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC